BAYN.DE Bayer Aktiengesellschaft
Company Analysis
Latest News
Bayer Kerendia slows kidney disease, marking fifth straight Phase III success
Bayer reported positive Phase III FIND-CKD trial results for its drug Kerendia (finerenone). The drug significantly slowed kidney disease progression in...
🔴 Bayer Aktiengesellschaft is trading 5.2% down today on fresh Roundup settlement uncertainty
Bayer Aktiengesellschaft is trading 5.2% down at €33.30 after fresh uncertainty emerged regarding its proposed $7.25 billion U.S. Roundup weedkiller...
🔴 Bayer (BAYN.DE) slumps over 5% on renewed uncertainty over $7.25B Roundup settlement
Bayer Aktiengesellschaft is trading at €33.30 (-5.21%) after news of a fresh legal obstacle in the company's long-running Roundup weedkiller litigation renewed...
Bayer NUBEQA Beats Rival on Cognitive Safety in Prostate Cancer Trial
Bayer presented primary Phase II ARACOG trial results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The head-to-head study met its...
Bayer Faces Antitrust Lawsuit, Allegedly Blocking Generic GMO Corn Seeds
Iowa-based Latham Quality Seed filed a federal antitrust lawsuit against Bayer for allegedly monopolizing the genetically modified (GMO) corn seed market. The...
Bayer $7.25 billion Roundup settlement stalls, following federal court move
Bayer faces potential delays for its proposed $7.25 billion settlement involving thousands of Roundup cancer claims. An opposing attorney escalated legal...